Table 1 Characteristics of selected biomarkers for therapy monitoring in MIS-C.
Marker | Cut-off point | Sensitivity | Specificity | Likelihood ratio* |
---|---|---|---|---|
Comparison of acute MIS-C cases to remission (monitoring of therapy efficacy) | ||||
Early classical pathway activation marker C1s-C1-inhibitor complex | 1795 ng/mL | 91.18 77.04–96.95 | 90.91 76.43–96.86 | 10.029 (3.392–29.651) |
Alternative pathway activation product Bb | 1.11 ug/mL | 96.77 83.81–99.83 | 93.94 80.39–98.92 | 15.968 (4.161–61.274) |
Anaphylatoxin C3a | 170 ng/mL | 100 77.19–100 | 85.71 60.06–97.46 | 7.000 (1.940–25.255) |
Terminal pathway activation product sC5b-9 | 363 ng/mL | 79.4 63.20–89.65 | 75.76 58.98–87.17 | 3.276 (1.750–6.132) |
Macrophage activation marker neopterin | 10.7 nmol/L | 100 88.65–100 | 100 89.57–100 | inf (nan-inf) |